Black Canyon Bio (BCB) is developing novel products for treating cancer using our proprietary Specific Neo-Antigen Peptides (SNAP) Technology platform. SNAP Technology has product development applications across many cancers and other diseases.
SNAP Technology was developed by Dr. Sunil Sharma and his team at the Translational Genomics Research Institute (TGen), part of the City of Hope Medical Network, where Dr. Sharma is a Deputy Director of Clinical Sciences and Professor and Division Director of Applied Cancer Research and Drug Discovery, and directs the City of Hope Center for Cancer Prevention and Early Detection.
BCB’s first two products, SNAP-Vac (a personalized cancer vaccine) and SNAP-TIL (a personalized cellular therapy) will start human clinical testing in 2024. The market for cancer vaccines and cellular therapies is expected to grow exponentially during the next decade, and these SNAP-based cancer treatments have the potential to be leading products.
Company Details
- Employees
- 5
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://blackcanyonbio.com
- Keywords
- Fairfax.
Black Canyon Bio Questions
Black Canyon Bio's website is http://blackcanyonbio.com
Black Canyon Bio's LinkedIn profile is https://www.linkedin.com/company/black-canyon-bio
Black Canyon Bio has
5 employees.
View email and phone details for 5
employees at Black Canyon Bio.
Black Canyon Bio's industry is
Biotechnology Research
Black Canyon Bio's top competitors are
Zeplo,
Grit Bio, Inc.,
Oncomyx Therapeutics,
Kamino Global, Llc,
Black Canyon Consulting Llc,
Miie Lab,
The Bioforge Group, Llc,
Coastar Therapeutics,
Taskerio,
Slam Biotherapeutics.
Black Canyon Bio's categories are Biotechnology Research
